NASDAQ · SOPH
SOPHiA GENETICS SA financials
$8.30−2.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $77.3M | $65.2M | $62.4M | $47.6M | $40.5M |
| Gross profit | $52.1M | $43.9M | $42.9M | $31.3M | $25.2M |
| Gross margin | 67.4% | 67.4% | 68.8% | 65.7% | 62.4% |
| Operating income | -$70.9M | -$66.6M | -$74.8M | -$87.8M | -$71.5M |
| Net income | -$79.0M | -$62.5M | -$79.0M | -$87.4M | -$73.7M |
| Net margin | −102.2% | −95.9% | −126.6% | −183.9% | −182.1% |
| Diluted EPS | $-1.17 | $-0.95 | $-1.22 | $-1.36 | $-1.33 |
| EBITDA | -$61.4M | -$58.0M | -$66.5M | -$82.3M | -$67.9M |
| Operating cash flow | -$35.9M | -$44.5M | -$53.2M | -$70.1M | -$57.9M |
| Free cash flow | -$36.5M | -$44.8M | -$54.7M | -$80.0M | -$64.5M |
| Diluted shares | 67.5M | 66.1M | 64.8M | 64.1M | 55.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $70.3M | $80.2M | $123.3M | $161.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $47.7M | $13.2M | $0.00 | $0.00 |
| Total assets | $163.0M | $155.3M | $206.2M | $243.8M |
| Total liabilities | $115.9M | $58.8M | $54.7M | $43.7M |
| Shareholders' equity | $47.1M | $96.5M | $151.4M | $200.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology